Key Insights

Highlights

Success Rate

100% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

0.0%

0 terminated out of 9 trials

Success Rate

100.0%

+13.5% vs benchmark

Late-Stage Pipeline

33%

3 trials in Phase 3/4

Results Transparency

14%

1 of 7 completed with results

Key Signals

1 with results100% success

Data Visualizations

Phase Distribution

9Total
P 1 (3)
P 2 (3)
P 3 (2)
P 4 (1)

Trial Status

Completed7
Not Yet Recruiting2

Trial Success Rate

100.0%

Benchmark: 86.5%

Based on 7 completed trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT06679959Phase 1CompletedPrimary

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of ASC30 Injection in Participants With Obesity

NCT07654374Phase 3Not Yet Recruiting

A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)

NCT07654361Phase 3Not Yet Recruiting

Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)

NCT06703021Phase 2Completed

A Dose-Range Study of Aleniglipron (GSBR-1290) in Participants Living With Obesity or Overweight With at Least One Weight-related Comorbidity

NCT06972992Phase 1CompletedPrimary

A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASC47 in Combination With Semaglutide

NCT07002905Phase 2CompletedPrimary

A Study to Evaluate the Efficacy, Safety, and Tolerability in Participants With Obesity or Overweight With Weight-Related Comorbidities

NCT06671821Phase 2CompletedPrimary

Long-term Efficacy and Safety of HRS-7535 Tablets in Obese Subjects

NCT06427590Phase 1CompletedPrimary

A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASC47 in Healthy and Obese Subjects

NCT01987427Phase 4CompletedPrimary

A Multicenter, Double-blind, Randomized, Parallel-group, Pilot Study of 12-week Duration to Assess the Short-term Safety and Tolerability of Lorcaserin Plus Two Doses of Immediate-Release Phentermine-HCl Compared With Lorcaserin Alone in Overweight and Obese Adults

Showing all 9 trials

Research Network

Activity Timeline